Thousands of diabetics are facing a potential change in their medication regime following a new decision from the Danish Medicines Agency, which tightens the rules for subsidies for certain diabetes medications. This measure affects patients with type 2 diabetes in particular, where up to 49,000 individuals may need to switch to a cheaper medical alternative before they can receive subsidies for drugs like Ozempic.
The Danish Diabetes Association has expressed concern about this change, fearing that it will create uncertainty and insecurity among diabetics. “It can be very stressful for patients to have to change medication, and it can potentially worsen the treatment of their condition during the period when the new drugs are being tested,” explains Tanja Thybo, research director at the Danish Diabetes Association.
This decision has also been criticized for undermining trust in the clinical judgment of general practitioners. “It undermines the trust that patients have in their doctors when official sources doubt doctors’ choice of medication,” says Thybo.
The tightening of the rules is motivated by a desire to reduce costs. The regions, which cover a large part of the expenses for diabetes medication, have experienced increased budget pressures, partly due to a significant increase in the use of Ozempic. The price of this drug is almost twice as high as the cheaper alternatives, which has motivated the Danish Medicines Agency’s decision.
The Danish Medicines Agency has explained that by requiring patients to first try cheaper alternatives, significant savings can be achieved in the healthcare budget. “We understand the concerns that the change brings, but it is also important to consider the economic aspects and ensure a sustainable management of our healthcare resources,” a spokesperson from the agency states.
This change will take effect soon, and affected patients will be informed through their doctors about the next steps in the process of switching medication.